CoChat

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).

Kopetz, Scott, McDonough, Shannon L, Morris, Van Karlyle, Lenz, Heinz-Josef, Magliocco, Anthony Martin, Atreya, Chloe Evelyn, Diaz, Luis A., Allegra, Carmen Joseph, Wang, Stephen E., Lieu, Christopher Hanyoung, Eckhardt, S. Gail, Semrad, Thomas John, Kaberle, Kimberly, Guthrie, Katherine A, Hochster, Howard S. · 2017 · Journal of Clinical Oncology
Cited by 102

The DOI matches its Crossref record.

Abstract

520 Background: BRAF V600 mutations are associated with rare objective responses to the mutated BRAF inhibitor vemurafenib in patients with mCRC. Blockade of BRAF V600 by vemurafenib causes feedback upregulation of EGFR, whose signaling activities can be impeded by cetuximab. In murine models of BRAF V600 mCRC, the combination of irinotecan, cetuximab, and vemurafenib leads to greater anti-tumor activity, as suggested by a prior Phase 1B study. Methods: Patients (pts) with BRAF V600 mutated and extended RAS wild-type mCRC were randomized to irinotecan (180 mg/m 2 IV every 14 days) and cetuximab (500 mg/m 2 IV every 14 days) with or without vemurafenib (960 mg PO twice daily). Patients had received 1 or 2 prior regimens, with no prior anti-EGFR agents, although prior irinotecan was allowed. Crossover from the control arm to the experimental arm was allowed after documented progression. The primary endpoint was progression-free survival (PFS, investigator assessed), with 90% power to detect a HR of 0.5, with two-sided type 1 error of 5%. Results: 106 patients were enrolled (54 in the experimental arm) from 12/2014 to 4/2016, with ECOG PS ≤ 1. Median age of 62 years, 59% female, and prior irinotecan therapy in 39%. PFS was improved with the addition of vemurafenib (HR = 0.42, 95% confidence interval [CI] of 0.26 to 0.66, P < 0.001) with median PFS of 4.4 (95% CI: 3.6 – 5.7) months vs 2.0 (95% CI: 1.8 – 2.1). Response rate was 16% vs 4% (P = 0.09), with disease control rate of 67% vs 22% (P < 0.001). Grade 3/4 adverse events higher in the experimental arm included neutropenia (28% vs 7%), anemia (13% vs 0%), and nausea (15% vs 0%). There was no increase in skin toxicity or fatigue. No new safety signal was observed. Approximately 50% of patients in the control aim crossed over at the time of progression. Overall survival and efficacy at cross-over data remain immature. Conclusions: The addition of vemurafenib to the combination of cetuximab and irinotecan resulted in a prolongation of progression-free survival and a higher disease control rate, indicating that simultaneous EGFR and BRAF inhibition is effective in BRAF V600 mutated CRC. Clinical trial information: NCT02164916.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.35.4_suppl.520

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 102

Metadata

Authors
Kopetz, S., McDonough, S. L., Morris, V. K., Lenz, H.-J., Magliocco, A. M., Atreya, C. E., Diaz, L. A., Allegra, C. J., Wang, S. E., Lieu, C. H., Eckhardt, S. G., Semrad, T. J., Kaberle, K., Guthrie, K. A., & Hochster, H. S.
Venue
Journal of Clinical Oncology
Published
2017-02-01
Volume
35
Issue
4_suppl
Pages
520-520
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4248090744
Cited by
102
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). https://app.cochat.ai/papers/10.1200/jco.2017.35.4_suppl.520
The paper
Kopetz, S., McDonough, S. L., Morris, V. K., Lenz, H.-J., Magliocco, A. M., Atreya, C. E., Diaz, L. A., Allegra, C. J., Wang, S. E., Lieu, C. H., Eckhardt, S. G., Semrad, T. J., Kaberle, K., Guthrie, K. A., & Hochster, H. S. (2017). Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.35.4_suppl.520

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.